262results about How to "Good skin permeability" patented technology

An apparatus to rapidly deliver a drug to a patient, the invention comprising the method of locating a drug beneath a patient's skin in a drug depot site, placing a heating component near the drug depot site and generating heat in and near the drug depot site. A control component connected to the heating component is used to control the magnitude and duration of heat generated by the heating component.

A patch comprising a backing layer and an adhesive layer disposed on the backing layer and compounded with a drug and an adhesive base agent, wherein the adhesive base agent comprises styrene-isoprene-styrene block copolymer, 2-ethylhexyl acrylate—vinyl acetate copolymer and a basic nitrogen-including polymer including a basic nitrogen and having no adhesion property at normal temperature.

A topical composition, specifically an oil-in-water emulsion, comprised of ketoprofen and oxybenzone in a physiologically acceptable topical carrier. The composition is applied topically to alleviate pain, especially pain associated with migraine headache. The composition has good photostability as well as freeze / thaw stability.

The present invention relates to a peptide having the activity of insulin like growth factor-1 (IGF-1) and derived from IGF-1, a composition for improving skin conditions or treating a periodontal disease comprising the peptide. The IGF-1 mimicking peptides of this invention have identical functions or actions to natural-occurring IGF-1 and much better stability and skin permeation than natural-occurring IGF-1. In these connections, the composition comprising the peptides of this invention can exhibit excellent efficacies on the treatment, prevention and improvement of diseases or conditions demanding IGF-1 activities. In addition, the peptides of this invention can be advantageously applied to pharmaceutical compositions, quasi-drugs and cosmetics.

The present invention relates to an active transdermal drug delivery system performing transdermal drug delivery comprising of a patch capable of being attachable to the skin of the subject; at least one electrical energy power input; a plurality of converters / energy transducers configured for converting the electrical energy to different forms of energy; and a controller including a programmable microprocessor configured for providing the intensity, sequence, nature, and timing information for the different energies supplied and thereby providing activating signals to the said converters for the transdermal drug delivery by the said patch, and a method for performing transdermal drug delivery using said electronic patch.

Method of exfoliating mammalian skin comprising the step of using a foam applicator to apply a personal care composition to delicate mammalian skin, wherein the foam applicator comprises a material selected from the group consisting of polyester, polyurethane, polyether, polyethylene, polystyrene, cross-linked polyethylene, and mixtures thereof, and has a porosity of from about 10 to about 110 pores per square inch; and wherein the personal care composition comprises a dermatologically-acceptable carrier in the form of an emulsion.

The nanometer antifungal econazole nitrate emulsion medicine consists of econazole nitrate, surfactant, oil and distilled water. Its preparation process includes the following steps: weighing the materials; mixing the surfactant and oil and dissolving econazole nitrate in dimethyl sulphoxide; mixing the solution of econazole nitrate with the surfactant and oil; and final adding distilled water slowly while stirring to form stable homogeneous transparent nanometer antifungal econazole nitrate emulsion medicine. The medicine is used in treating candidal tinea corporis, tinea cruris and tinea pedis, aural mycosis, seborrheic dermatitis, etc. The medicine is absorbed through skin to enter into blood circulation, and this avoids the first pass effect of liver, prolongs the medicine release and prevents stimulation to gastrointestinal tract. The preparation process is simple and low in power consumption.

The invention relates to the transdermal application of oligopeptides for reducing synaptic transmission in tissues of an animal. In one aspect, this invention relates to compositions comprising an oligopeptide and optionally a carrier comprising a positively charged “backbone” having positively charged branching or “efficiency” groups, as described herein. Most preferably the positively charged carrier is a long-chain positively charged polypeptide or a positively charged nonpeptidyl polymer, for example, a polyalkyleneimine. The invention further relates methods for producing a biologic effect of reducing synaptic transmission in a tissue by topically applying an effective amount of such a composition, preferably to the skin, of a subject or patient in need of such treatment. This invention also provides kits for preparing or formulating a composition that comprises the oligopeptide and optionally a carrier, as well as such additional items that are needed to produce a usable formulation, or a premix that may in turn be used to produce such a formulation.

A cosmetic composition with superior moisturizing benefits comprising from approximately 0.3% to approximately 0.9% by weight of bio-chelated mineral blend comprising silicon, magnesium, copper, iron, zinc, and calcium, and at least approximately 85.0% by weight of a humectant blend. Preferably, the bio-chelated mineral blend comprise Saccharomyces zinc ferment, Saccharomyces copper ferment, Saccharomyces magnesium ferment, Saccharomyces iron ferment, Saccharomyces silicon ferment, and Saccharomyces calcium ferment in equal amounts, more preferably from approximately 0.05% to approximately 0.15% by weight of each component. The humectant blend preferably comprises glycerin, beet root extract, and Aloe barbadensis leaf polysaccharides.

The present invention relates to pharmaceutical formulations comprising at least two compounds, one effecting opioid analgesia and one effecting cyclooxygenase 1 and 2 activity, in amounts sufficient to potentiate an antinociceptive response when both compounds are topically administered in a physiologically acceptable topical excipient. The pharmaceutical formulations of the present invention are used to prevent or relieve acute pain and chronic peripheral neuropathy and / or neuropathic inflammation in a patient in need of such treatment.